Immunotherapy for glioma: Current management and future application

被引：532

作者：

Xu, Shengchao ^{[1
]}

Tang, Lu ^{[2
]}

Li, Xizhe ^{[2
]}

Fan, Fan ^{[1
]}

Liu, Zhixiong ^{[1
]}

机构：

[1] Cent South Univ, Dept Neurosurg, Xiangya Hosp, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China

[2] Cent South Univ, Dept Thorac Surg, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China

来源：

CANCER LETTERS | 2020年 / 476卷

基金：

中国国家自然科学基金;

关键词：

Glioma; Immunotherapy; Checkpoint; Oncolytic virus; Vaccine; TUMOR-ASSOCIATED MACROPHAGES; CENTRAL-NERVOUS-SYSTEM; DENDRITIC CELL VACCINATION; BLOOD-BRAIN-BARRIER; LONG-TERM SURVIVAL; REGULATORY T-CELLS; I CLINICAL-TRIAL; MALIGNANT GLIOMA; GLIOBLASTOMA-MULTIFORME; RECURRENT GLIOBLASTOMA;

D O I：

10.1016/j.canlet.2020.02.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells. Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved limited improvements in the prognosis of glioma patients. Immunotherapy, a revolution in cancer treatment, has become a promising strategy with the ability to penetrate the blood-brain barrier since the pioneering discovery of lymphatics in the central nervous system. Here we detail the current management of gliomas and previous studies assessing different immunotherapies in gliomas, despite the fact that the associated clinical trials have not been completed yet. Moreover, several drugs that have undergone clinical trials are listed as novel strategies for future application; however, these clinical trials have indicated limited efficacy in glioma. Therefore, additional studies are warranted to evaluate novel therapeutic approaches in glioma treatment.

引用

页码：1 / 12

页数：12

共 163 条

[1] HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial [J].

Ahmed, Nabil ;

Brawley, Vita ;

Hegde, Meenakshi ;

Bielamowicz, Kevin ;

Kalra, Mamta ;

Landi, Daniel ;

Robertson, Catherine ;

Gray, Tara L. ;

Diouf, Oumar ;

Wakefield, Amanda ;

Ghazi, Alexia ;

Gerken, Claudia ;

Yi, Zhongzhen ;

Ashoori, Aidin ;

Wu, Meng-Fen ;

Liu, Hao ;

Rooney, Cliona ;

Dotti, Gianpietro ;

Gee, Adrian ;

Su, Jack ;

Kew, Yvonne ;

Baskin, David ;

Zhang, Yi Jonathan ;

New, Pamela ;

Grilley, Bambi ;

Stojakovic, Milica ;

Hicks, John ;

Powell, Suzanne Z. ;

Brenner, Malcolm K. ;

Heslop, Helen E. ;

Grossman, Robert ;

Wels, Winfried S. ;

Gottschalk, Stephen .

JAMA ONCOLOGY, 2017, 3 (08) :1094-1101

[2] HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors [J].

Ahmed, Nabil ;

Salsman, Vita S. ;

Kew, Yvonne ;

Shaffer, Donald ;

Powell, Suzanne ;

Zhang, Yi J. ;

Grossman, Robert G. ;

Heslop, Helen E. ;

Gottschalk, Stephen .

CLINICAL CANCER RESEARCH, 2010, 16 (02) :474-485

[3] Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model [J].

Alessandrini, Francesco ;

Menotti, Laura ;

Avitabile, Elisa ;

Appolloni, Irene ;

Ceresa, Davide ;

Marubbi, Daniela ;

Campadelli-Fiume, Gabriella ;

Malatesta, Paolo .

ONCOGENE, 2019, 38 (23) :4467-4479

[4] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[5]

[Anonymous], PHASE 1 STUDY REPEAT

[6]

[Anonymous], ANN ONCOL

[7] Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial [J].

Ardon, Hilko ;

Van Gool, Stefaan W. ;

Verschuere, Tina ;

Maes, Wim ;

Fieuws, Steffen ;

Sciot, Raf ;

Wilms, Guido ;

Demaerel, Philippe ;

Goffin, Jan ;

Van Calenbergh, Frank ;

Menten, Johan ;

Clement, Paul ;

Debiec-Rychter, Maria ;

De Vleeschouwer, Steven .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (11) :2033-2044

[8] Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study [J].

Ardon, Hilko ;

Van Gool, Stefaan ;

Lopes, Isabel Spencer ;

Maes, Wim ;

Sciot, Raf ;

Wilms, Guido ;

Demaerel, Philippe ;

Bijttebier, Patricia ;

Claes, Laurence ;

Goffin, Jan ;

Van Calenbergh, Frank ;

De Vleeschouwer, Steven .

JOURNAL OF NEURO-ONCOLOGY, 2010, 99 (02) :261-272

[9] Adjuvant Dendritic Cell-Based Tumour Vaccination for Children With Malignant Brain Tumours [J].

Ardon, Hilko ;

De Vleeschouwer, Steven ;

Van Calenbergh, Frank ;

Claes, Laurence ;

Kramm, Christof M. ;

Rutkowski, Stefan ;

Wolff, Johannes E. A. ;

Van Gool, Stefaan W. .

PEDIATRIC BLOOD & CANCER, 2010, 54 (04) :519-525

[10] Flow cytometric characterization of tumor-associated macrophages in experimental gliomas [J].

Badie, B ;

Schartner, JM .

NEUROSURGERY, 2000, 46 (04) :957-961

← 1 2 3 4 5 6 7 8 9 10 →